A Humabody-based therapeutic that has agonist activity against CD137 (4-1BB, HGNC:TNFRSF9) continent upon expression of prostate-specific membrane antigen in the tumour microenvironment, CB307, has recently begun clinical studies [38] and may provide the first clinical evidence of this hypothesis. Here, TNFRSF9 is linked to neoplasm.